Fennec Pharmaceuticals Inc.
TSX:FRX.TOBiotechnology
-$0.22 today
- Market cap
- $676.80M
- Beta
- 1.08
- P/E (TTM)
- -36.5
- EPS (TTM)
- -$0.24
Volume 0.00M
Average 0.00M
FRX.TO Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Fennec Pharmaceuticals Inc.TSX: FRX.TO
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables turns positive
Q1 FY2026 accounts receivables was $4.5M, compared with -$5.28M a year earlier. Trailing-twelve-month accounts receivables was -$2.72M. Over 3 fiscal years it compounded at +100.4% a year.
Context
- Accounts receivables amounted to 27.9% of revenue in FY2025, up 11.3 pp from a year earlier.
- Accounts receivables grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts receivables holds near $4.5M or moves back toward the trailing-twelve-month quarterly average of -$679.17K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (12.44M) USD
- Year-over-year change
- -58.0%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (12.44M) | -58.0% |
| FY2024 | 2024-12-31 | (7.87M) | -8.3% |
| FY2023 | 2023-12-31 | (7.27M) | -370.5% |
| FY2022 | 2022-12-31 | (1.55M) | — |
| FY2021 | 2021-12-31 | 0 | — |
Accounts Receivables vs competitors
How FRX.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -76.8% is the 5th highest of 8, against a peer median of +133.2%.
- Accounts receivables amounts to 5.3% of revenue for FRX.TO, versus a peer median of 5.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$34.55M CAD | +870.4% | — | 11.1% | |
| LTM Mar 2026 | CA$15.58M CAD | +1667.9% | — | 5.7% | |
| LTM Mar 2026 | $6.55M USD | -297.0% | +15.7% | 2.1% | |
PRN.TOProfound Medical Corp. | LTM Mar 2026 | $3.48M USD | -925.6% | -55.1% | 18.6% |
| LTM Mar 2026 | $2.72M USD | -76.8% | +100.4% | 5.3% | |
| LTM Mar 2026 | $1.08M USD | +133.2% | -23.4% | 0.4% | |
| LTM Mar 2026 | $406.45K USD | +219.6% | — | — | |
| LTM Apr 2026 | CA$11K CAD | -119.6% | — | — | |
| Peer median (excluding FRX.TO) | — | +133.2% | -23.4% | 5.7% | |
Competitors are the stored peer set for FRX.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (17.35M) | (23.71M) | (16.05M) | (436K) | (9.74M) |
| Depreciation & Amortization | 0 | 0 | 0 | 800K | 103K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.02M | 4.22M | 5.35M | 5.06M | 7.03M |
| Change in Working Capital | (932K) | 1.1M | (6.78M) | 16.94M | (12.04M) |
| Accounts Receivables | 0 | (1.55M) | (7.27M) | (7.87M) | (12.44M) |
| Inventory | 0 | (576K) | (1.58M) | 579K | (1.28M) |
| Accounts Payables | (794K) | 1.61M | 1.39M | (537K) | 1.39M |
| Other Working Capital | (138K) | 1.61M | 683K | 24.77M | 282K |
| Other Non-Cash Items | 307K | 466K | 326K | 4.61M | (26.45K) |
| Operating Cash Flow | (14.22M) | (18.06M) | (17.14M) | 26.98M | (14.67M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 |
| Debt Repayment | 5M | 19.94M | 5M | (13M) | (19.82M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 45.01M |
| Common Stock Repurchased | 0 | (194K) | (78K) | (176K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (22K) | 797K | 1.64M | (439K) | (190.27K) |
| Financing Cash Flow | 4.98M | 20.73M | 6.64M | (13.62M) | 25.01M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | (1.5M) |
| Net Change in Cash | (9.24M) | 2.67M | (10.51M) | 13.37M | 8.83M |
| Free Cash Flow | (14.22M) | (18.06M) | (17.14M) | 26.98M | (14.67M) |
Fennec Pharmaceuticals Inc.
TSX:FRX.TO
Intrinsic Alpha fair value
Locked
Current Price
$19.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.